Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Randomized, Double-Blind, Vehicle-Controlled Clinical Trial With Separate Open-Label Active Treatment Phase Evaluating the Safety, Pharmacokinetics and Efficacy of FMX114 Gel in the Treatment of Mild-to-Moderate Atopic Dermatitis in Adults

NCT04927572 is registered in ClinicalTrials.gov with Vyne Therapeutics Inc. as lead sponsor.

NCT NCT04927572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04927572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Randomized, Double-Blind, Vehicle-Controlled Clinical Trial With Separate Open-Label Active Treatment Phase Evaluating the Safety, Pharmacokinetics and Efficacy of FMX114 Gel in the Treatment of Mild-to-Moderate Atopic Dermatitis in Adults
Lead sponsor
Vyne Therapeutics Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 13, 2021
Completion date
August 9, 2022
Enrollment
21 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis